Amyloid-β, p-tau, and reactive microglia load are correlates of MRI cortical atrophy in Alzheimer’s disease

INTRODUCTION The aim of this study was to identify the histopathological correlates of MRI cortical atrophy in (a)typical Alzheimer’s disease (AD) donors. METHODS 19 AD and 10 control donors underwent post-mortem in-situ 3T-3DT1-MRI, from which cortical thickness was calculated. Upon subsequent autopsy, 21 cortical brain regions were selected and immunostained for amyloid-beta, phosphorylated-tau, and reactive microglia. MRI-pathology associations were assessed using linear mixed models. Post-mortem MRI was compared to ante-mortem MRI when available. RESULTS Higher amyloid-beta load weakly correlated with a higher cortical thickness globally. Phosphorylated-tau strongly correlated with cortical atrophy in temporo-frontal regions. Reactive microglia load strongly correlated with cortical atrophy in the parietal region. Post-mortem scans showed high concordance with ante-mortem scans acquired <1 year before death. DISCUSSION Distinct histopathological markers differently correlate with cortical atrophy, highlighting their different roles in the neurodegenerative process. This study contributes in understanding the pathological underpinnings of MRI atrophy patterns.

[1]  W. M. van der Flier,et al.  Application of the ATN classification scheme in a population without dementia: Findings from the EPAD cohort , 2021, Alzheimer's & dementia : the journal of the Alzheimer's Association.

[2]  David T. Jones,et al.  New insights into atypical Alzheimer's disease in the era of biomarkers , 2021, The Lancet Neurology.

[3]  Theresa M. Harrison,et al.  Distinct effects of beta‐amyloid and tau on cortical thickness in cognitively healthy older adults , 2020, Alzheimer's & dementia : the journal of the Alzheimer's Association.

[4]  Guy B. Williams,et al.  Gray matter changes related to microglial activation in Alzheimer's disease , 2020, Neurobiology of Aging.

[5]  M. Gorno-Tempini,et al.  Distinct tau PET patterns in atrophy-defined subtypes of Alzheimer’s disease , 2019, Alzheimer's & Dementia.

[6]  Hitoshi Shimada,et al.  In vivo direct relation of tau pathology with neuroinflammation in early Alzheimer’s disease , 2019, Journal of Neurology.

[7]  J. Geurts,et al.  Post-Mortem MRI and Histopathology in Neurologic Disease: A Translational Approach , 2019, Neuroscience Bulletin.

[8]  D. Brooks,et al.  Microglial activation in early Alzheimer trajectory is associated with higher gray matter volume , 2019, Neurology.

[9]  B. Miller,et al.  Alzheimer’s disease clinical variants show distinct regional patterns of neurofibrillary tangle accumulation , 2019, bioRxiv.

[10]  Y. G. Graaf,et al.  Normal Aging Brain Collection Amsterdam (NABCA): A comprehensive collection of postmortem high-field imaging, neuropathological and morphometric datasets of non-neurological controls , 2019, NeuroImage: Clinical.

[11]  P. Scheltens,et al.  Can post-mortem MRI be used as a proxy for in vivo? A case study , 2019, Brain communications.

[12]  Clifford R. Jack,et al.  Imaging correlations of tau, amyloid, metabolism, and atrophy in typical and atypical Alzheimer's disease , 2018, Alzheimer's & Dementia.

[13]  Philip S. Insel,et al.  Associations between tau, Aβ, and cortical thickness with cognition in Alzheimer disease , 2019, Neurology.

[14]  P. Scheltens,et al.  Neuroinflammation is increased in the parietal cortex of atypical Alzheimer’s disease , 2018, Journal of Neuroinflammation.

[15]  W. M. van der Flier,et al.  Amsterdam Dementia Cohort: Performing Research to Optimize Care , 2018, Journal of Alzheimer's disease : JAD.

[16]  O. Pasternak,et al.  Cortical microstructural changes along the Alzheimer's disease continuum , 2018, Alzheimer's & Dementia.

[17]  H. Gertz,et al.  Inhomogeneous distribution of Alzheimer pathology along the isocortical relief. Are cortical convolutions an Achilles heel of evolution? , 2017, Brain pathology.

[18]  J. Clarimón,et al.  Longitudinal brain structural changes in preclinical Alzheimer's disease , 2017, Alzheimer's & Dementia.

[19]  Keith A. Johnson,et al.  Association of In Vivo [18F]AV-1451 Tau PET Imaging Results With Cortical Atrophy and Symptoms in Typical and Atypical Alzheimer Disease , 2017, JAMA neurology.

[20]  Nick C. Fox,et al.  Consensus classification of posterior cortical atrophy , 2017, Alzheimer's & Dementia.

[21]  W. Klunk,et al.  Post-mortem histopathology underlying β-amyloid PET imaging following flutemetamol F 18 injection , 2016, Acta neuropathologica communications.

[22]  Daniel R. Schonhaut,et al.  Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease. , 2016, Brain : a journal of neurology.

[23]  E. Mandelkow,et al.  Tau in physiology and pathology , 2015, Nature Reviews Neuroscience.

[24]  Frederik Barkhof,et al.  The behavioural/dysexecutive variant of Alzheimer's disease: clinical, neuroimaging and pathological features. , 2015, Brain : a journal of neurology.

[25]  Burkhard Becher,et al.  Immune attack: the role of inflammation in Alzheimer disease , 2015, Nature Reviews Neuroscience.

[26]  J. Clarimón,et al.  Cerebrospinal fluid β‐amyloid and phospho‐tau biomarker interactions affecting brain structure in preclinical Alzheimer disease , 2014, Annals of neurology.

[27]  Nick C Fox,et al.  Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria , 2014, The Lancet Neurology.

[28]  Sterling C. Johnson,et al.  Amyloid burden and neural function in people at risk for Alzheimer's Disease , 2014, Neurobiology of Aging.

[29]  Brian B. Avants,et al.  Histology-derived volumetric annotation of the human hippocampal subfields in postmortem MRI , 2014, NeuroImage.

[30]  P. Eikelenboom,et al.  Source (or Part of the following Source): Type Article Title Neuroinflammation in Alzheimer's Disease Wanes with Age Author(s) Neuroinflammation in Alzheimer's Disease Wanes with Age , 2022 .

[31]  C. Jack,et al.  Temporoparietal atrophy: A marker of AD pathology independent of clinical diagnosis , 2011, Neurobiology of Aging.

[32]  R. Petersen,et al.  Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study , 2011, The Lancet Neurology.

[33]  Mark A Mintun,et al.  Absence of Pittsburgh compound B detection of cerebral amyloid beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: a case report. , 2009, Archives of neurology.

[34]  Andrew King,et al.  Assessment of beta-amyloid deposits in human brain: a study of the BrainNet Europe Consortium. , 2009, Acta neuropathologica.

[35]  W. Jagust,et al.  Aβ amyloid and glucose metabolism in three variants of primary progressive aphasia , 2008, Annals of neurology.

[36]  Andrew King,et al.  Staging of Neurofibrillary Pathology in Alzheimer's Disease: A Study of the BrainNet Europe Consortium , 2008, Brain pathology.

[37]  S. DeKosky,et al.  Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease , 2008, Brain : a journal of neurology.

[38]  C. Jack,et al.  11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. , 2008, Brain : a journal of neurology.

[39]  R. Petersen,et al.  Clinical, genetic, and neuropathologic characteristics of posterior cortical atrophy , 2004, Neurology.

[40]  H. Braak,et al.  Phases of Aβ-deposition in the human brain and its relevance for the development of AD , 2002, Neurology.

[41]  C. Plata-salamán,et al.  Inflammation and Alzheimer’s disease , 2000, Neurobiology of Aging.

[42]  Anders M. Dale,et al.  Cortical Surface-Based Analysis I. Segmentation and Surface Reconstruction , 1999, NeuroImage.

[43]  S. M. Sumi,et al.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) , 1991, Neurology.

[44]  Andrew K. C. Wong,et al.  A new method for gray-level picture thresholding using the entropy of the histogram , 1985, Comput. Vis. Graph. Image Process..

[45]  Michael Ewers,et al.  Spreading of amyloid, tau, and microvascular pathology in Alzheimer's disease: findings from neuropathological and neuroimaging studies. , 2014, Journal of Alzheimer's disease : JAD.

[46]  Charles Duyckaerts,et al.  National Institute on Aging–Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach , 2011, Acta Neuropathologica.

[47]  H. Braak,et al.  Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.

[48]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .